Study or Subgroup	SSRI Events	SSRI Total	Placebo Events	Placebo Total	Weight	Risk Ratio M-H, Random, 95% CI
29060/448 (A)	14	106	1	51	7.0%	6.74 [0.91, 49.82]
29060/448 (B)	13	106	0	52	3.6%	13.37 [0.81, 220.68]
29060/785 (A)	7	103	1	27	6.7%	1.83 [0.24, 14.28]
29060/785 (B)	4	96	0	26	3.4%	2.51 [0.14, 45.10]
29060/785 (C)	9	107	0	26	3.5%	4.75 [0.29, 79.08]
29060/785 (D)	4	100	0	26	3.4%	2.41 [0.13, 43.32]
Ball et al (2014)	4	79	0	79	3.3%	9.00 [0.49, 164.43]
Claghorn et al. 1996	2	47	0	46	3.1%	4.90 [0.24, 99.28]
Dunbar et al. 1991	14	240	0	240	3.5%	29.00 [1.74, 483.39]
Higuchi et al. (A) 2011	5	161	0	86	3.4%	5.91 [0.33, 105.59]
Higuchi et al. (B) 2011	2	83	0	86	3.1%	5.18 [0.25, 106.28]
LVM-MD-06	1	79	0	93	2.8%	3.52 [0.15, 85.33]
MY-1045/BRL-029060/1 (PAR128) (A)	36	357	1	70	7.2%	7.06 [0.98, 50.64]
MY-1045/BRL-029060/1 (PAR128) (B)	12	351	0	70	3.5%	5.04 [0.30, 84.19]
Peselow et al. 1989a	5	40	0	42	3.4%	11.54 [0.66, 202.11]
Ratti et al. 2011	3	120	0	120	3.2%	7.00 [0.37, 134.07]
SCT-MD-13	4	132	0	135	3.3%	9.20 [0.50, 169.27]
SCT-MD-26	11	154	0	155	3.5%	23.15 [1.38, 389.40]
SCT-MD-27 (A)	12	136	1	67	6.9%	5.91 [0.79, 44.52]
SCT-MD-27 (B)	8	138	1	68	6.6%	3.94 [0.50, 30.88]
Trivedi et al. (A) 2004	4	156	1	75	5.9%	1.92 [0.22, 16.91]
Trivedi et al. (B) 2004	6	154	1	74	6.4%	2.88 [0.35, 23.52]
Wade et al. 2002	3	191	0	189	3.2%	6.93 [0.36, 133.20]
Total (95% CI)		**3236**		**1903**	**100.0%**	**5.37 [3.16, 9.12]**
Total events	183		7			

Heterogeneity: Tau² = 0.00; Chi² = 6.86, df = 22 (P = 1.00); I² = 0%

Test for overall effect: Z = 6.22 (P < 0.00001)